Abbott’s diagnostics can rule out Heart attack

New Study Shows Abbott's Novel Diagnostic Test has the Potential to Demonstrate Gold Standard Accuracy and Speed, Which Could Help Rule Out Heart Attacks Earlier at the Point of Care

Heart attack

Preliminary research indicates that a diagnostic test currently in development, which can be done at the patient’s side in minutes, has similar accuracy to a high-sensitive troponin test for early rule out of a heart attack

For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether someone is having a heart attack. New data found that a blood test done in as little as 15 minutes could identify nearly 56.7 percent of people at low-risk of experiencing a heart attack.

More than seven billion diagnostic tests are run every year to help physicians make accurate, timely decisions about a person’s medical treatment. Point-of-care diagnostic tests, can often provide results within minutes. The goal of with-patient diagnostic tests is to deliver results with accuracy similar to lab tests. The findings from the study indicate that this new point-of-care blood test could help physicians streamline how patients are triaged in the emergency room by reducing the time it takes to rule out a heart attack and accelerating a safe discharge for low-risk patients.

Initial findings indicate that, for a substantial proportion of patients, it may be possible to safely rule out heart attacks within 15 minutes of blood drawn in the emergency department. The research evaluated 354 adults 18 years and older who entered an emergency department with symptoms of acute coronary syndrome, such as a heart attack. The patients’ cardiac troponin levels, which have become the standard for aiding doctors in checking for a heart attack, were measured using two Abbott blood tests: the ARCHITECT High Sensitive Troponin-I and the i-STAT TnI-Nx, a point-of-care diagnostic test under development.

Also Read |  QR Code-Based Health Cards to be Reality in Delhi by August 2021

“When designing Abbott’s newest point-of-care cardiac testing, we wanted to combine the benefits of higher-sensitivity troponin tests with the speed of results when it matters most,” said Matt Bates, divisional vice president of research and development for point-of-care diagnostics at Abbott. “This initial data will help guide our research and development of the next generation of cardiac testing to help physicians and emergency departments make timely decisions with confidence.”